ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar High Tech Center (ChemRar), the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Company, have announced collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry.

Through the partnership ChemRar and Lancet plan to develop and manufacture new drugs in major therapeutic areas which are a high priority for the Russian Federation healthcare system according to the significant Government strategy PHARMA-2020. The parties have agreed to co-invest in the further development of production capacities in order to localize the pharmaceutical production in the Russian Federation. The companies are supposed to carry out joint activity with use of complementary competences in development, production, distribution and marketing of innovative medicines in Russia and EEU (the Eurasian Economic Union).

According to Dmitry Sitnikov, CEO of Lancet: "Lancet develops its business in a strategic partnership with the leading producers of innovative medical products. We highly appreciate ChemRar's expertise and experience and we hope that our collaboration will allow us to successfully transform scientific achievements into quality products, and investment in development of production capacities on the basis of ChemRar will accelerate the development of the Russian pharmaceutical industry".

"The aim of ChemRar High Tech Center is to combine industrial and academic efforts in research and development of new medicines. We are actively involved in partnership with the major national and international pharmaceutical programs with our partners in Russia and worldwide. The partnership with Lancet is an excellent opportunity for the development of medical innovations in Russia, and improving access to medicines and better healthcare for Russian people", - Andrey Ivashchenko, Chairman of the board of directors of ChemRar, said.